<DOC>
	<DOC>NCT02693574</DOC>
	<brief_summary>Comparison Efficacy of 14-day Triple Therapy between Clarithromycin and levofloxacin on the Eradication of Helicobacter Pylori in Syrian population</brief_summary>
	<brief_title>Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori</brief_title>
	<detailed_description />
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Ofloxacin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>1Patients are aged greater than 18 years old who have H. pylori infection diagnosed by any of following three methods: IPositive rapid urease test (CLOtest). IIHistologic evidence of H. pylori by modified Giemsa staining. IIIPositive 13Curea breath test. without prior eradication therapy and are willing to receive therapy. 1. Children and teenagers aged less than 18 years. 2. Previous eradication treatment for H. pylori. 3. Patients who took any drug, which could influence the study results such as proton pump inhibitor, H2 blocker, mucosal protective agent and antibiotics. 4. History of gastrectomy. 5. Gastric malignancy, including adenocarcinoma and lymphoma, 6. Previous allergic reaction to antibiotics (Amoxicillin, Clarithromycin, Levofloxacin) and prompt pump inhibitors (Esomeprazole). 7. Contraindication to treatment drugs. 8. Pregnant or lactating women. 9. Severe concurrent disease. 10. Liver cirrhosis. 11. Chronic kidney disease. 12. Patients who cannot give informed consent by himself or herself.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Helicobacter pylori</keyword>
	<keyword>Helicobacter Infections</keyword>
	<keyword>Proton Pump Inhibitors</keyword>
</DOC>